Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Farletuzumab in Low CA125 Platinum-Sensitive Ovarian Cancer
NCT02289950Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2015
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of farletuzumab in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by Eisai Co., Ltd.. Started Mar 2015; status: completed.
02
Drugs
farletuzumab
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT02289950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02289950.